PMID- 21627744
OWN - NLM
STAT- MEDLINE
DCOM- 20120601
LR  - 20171116
IS  - 1445-5994 (Electronic)
IS  - 1444-0903 (Linking)
VI  - 42
IP  - 1
DP  - 2012 Jan
TI  - Monocyte chemoattractant protein-1 is associated with silent cerebral infarction 
      in patients on haemodialysis.
PG  - 29-34
LID - 10.1111/j.1445-5994.2011.02538.x [doi]
AB  - BACKGROUND: In patients with chronic renal failure undergoing haemodialysis (HD), 
      silent cerebral infarctions (SCI) are associated with high mortality. Levels of 
      monocyte chemoattractant protein-1 (MCP-1) increase with renal dysfunction and 
      may be a novel predictor for cerebrovascular events. We tested the hypothesis 
      that increased MCP-1 concentration correlate with the occurrence of SCI in HD 
      patients. METHODS: Using cranial magnetic resonance imaging (MRI) findings, 52 
      Japanese patients undergoing HD were divided into two groups: with SCI (61 +/- 7 
      years, mean +/- SD, n= 28) and without SCI (60 +/- 6 years, n= 24). The gender, 
      metabolic profiles and MCP-1 concentration were compared between the two groups. 
      RESULTS: The level of MCP-1 was higher in the with-SCI group than in the 
      without-SCI group (P < 0.0001). The proportion of smokers was higher in the 
      with-SCI group (P < 0.05) than in the without-SCI group. Plasma level of 
      high-density lipoprotein cholesterol was lower, while uric acid level was higher, 
      in the with-SCI group (P < 0.05 and P < 0.05 respectively) compared to the 
      without-SCI group. Multiple logistic regression analysis identified MCP-1 level 
      as being significantly associated with the presence of SCI (odds ratio 1.48, 95% 
      confidence interval = 1.10-5.75, P < 0.0001). CONCLUSIONS: This study indicates 
      that patients with chronic renal failure who are maintained on HD exhibit an 
      increased prevalence of SCI, and that MCP-1 is significantly associated with the 
      presence of SCI in HD patients.
CI  - (c) 2011 The Authors. Internal Medicine Journal (c) 2011 Royal Australasian College 
      of Physicians.
FAU - Uchida, E
AU  - Uchida E
AD  - Department of Nephrology, Tsukumi Central Hospital, Oita, Japan.
FAU - Anan, F
AU  - Anan F
FAU - Masaki, T
AU  - Masaki T
FAU - Kaneda, K
AU  - Kaneda K
FAU - Nawata, T
AU  - Nawata T
FAU - Eshima, N
AU  - Eshima N
FAU - Saikawa, T
AU  - Saikawa T
FAU - Yoshimatsu, H
AU  - Yoshimatsu H
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PL  - Australia
TA  - Intern Med J
JT  - Internal medicine journal
JID - 101092952
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Aged
MH  - Asymptomatic Diseases
MH  - Biomarkers
MH  - Brain Ischemia/blood/etiology
MH  - Cerebral Infarction/*blood/epidemiology/etiology
MH  - Chemokine CCL2/*blood
MH  - Comorbidity
MH  - Female
MH  - Humans
MH  - Japan/epidemiology
MH  - Kidney Failure, Chronic/blood/*complications/therapy
MH  - Magnetic Resonance Imaging
MH  - Male
MH  - Metabolic Syndrome/epidemiology
MH  - Middle Aged
MH  - Polypharmacy
MH  - Prevalence
MH  - Prospective Studies
MH  - *Renal Dialysis
MH  - Risk Factors
MH  - Smoking/epidemiology
EDAT- 2011/06/02 06:00
MHDA- 2012/06/02 06:00
CRDT- 2011/06/02 06:00
PHST- 2011/06/02 06:00 [entrez]
PHST- 2011/06/02 06:00 [pubmed]
PHST- 2012/06/02 06:00 [medline]
AID - 10.1111/j.1445-5994.2011.02538.x [doi]
PST - ppublish
SO  - Intern Med J. 2012 Jan;42(1):29-34. doi: 10.1111/j.1445-5994.2011.02538.x.